Weight Change Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome

Weickert MO, Kaltsas G, Hoersch D, Lapuerta P, Pavel ME, Valle JW, Caplin ME, Bergsland E, Kunz PL, Anthony LB, Grande E, Oberg K, Welin S, Warner RRP, Lombard-Bohas C, Fleming R, Kittur A, Arnold K, Yang QM, Kulke MH (2018)

Publication Type: Journal article

Publication year: 2018

Journal

Pancreas Lippincott, Williams & Wilkins

Book Volume: 47

Pages Range: 357-358

Journal Issue: 3

DOI: 10.1530/endoabs.52.p25

Authors with CRIS profile

Marianne Ellen Pavel Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology

Involved external institutions

University Hospitals Coventry and Warwickshire

United Kingdom (GB) Lexicon Pharmaceuticals, Inc.

United States (USA) (US) Uppsala University

Sweden (SE) Hospices Civils de Lyon (CHU)

France (FR) Stanford University

United States (USA) (US) University of Kentucky

United States (USA) (US) Icahn School of Medicine at Mount Sinai

United States (USA) (US) University of Manchester

United Kingdom (GB) Royal Free Hospital

United Kingdom (GB) Hospital Universitario Ramón y Cajal

Spain (ES) UCSF Helen Diller Family Comprehensive Cancer Center

United States (USA) (US) Dana–Farber Cancer Institute

United States (USA) (US) Zentralklinikum Bad Berka

Germany (DE)

How to cite

APA:

Weickert, M.O., Kaltsas, G., Hoersch, D., Lapuerta, P., Pavel, M.E., Valle, J.W.,... Kulke, M.H. (2018). Weight Change Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome. Pancreas, 47(3), 357-358. https://dx.doi.org/10.1530/endoabs.52.p25

MLA:

Weickert, Martin O., et al. "Weight Change Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome." Pancreas 47.3 (2018): 357-358.

BibTeX: Download